TABLE 2.
Factor | No. of patients |
Odds ratio (95% confidence interval) | P value | |
---|---|---|---|---|
Total | With favorable outcome | |||
Age (yr) | ||||
≤20 | 3 | 0 | NA | 0.491 |
>20–≤40 | 9 | 4 | 1 | |
>40–<60 | 14 | 7 | 1.250 (0.233–6.715) | 1.000 |
≥60 | 1 | 0 | NA | 1.000 |
Gender | ||||
Male | 21 | 7 | 1 | |
Female | 6 | 4 | 4.000 (0.584–27.411) | 0.187 |
Drug resistance pattern | ||||
Simple MDR | 6 | 4 | 1 | |
Pre-XDR | 12 | 5 | 0.357 (0.046–2.771) | 0.620 |
XDR | 9 | 2 | 0.143 (0.014–1.444) | 0.136 |
Dosage (mg/day) | ||||
500 | 23 | 8 | 1 | |
750 | 4 | 3 | 5.625 (0.500–63.282) | 0.273 |
MIC (μg/ml) | ||||
<32 | 22 | 11 | 1 | |
≥32 | 5 | 0 | NA | 0.06 |
Cmax (μg/ml) | ||||
≤20 | 11 | 3 | 0.429 (0.081–2.277) | 0.428 |
>20–<35 | 15 | 7 | 1 | |
≥35 | 1 | 1 | NA | 1.00 |
Cmax/MIC | ||||
<1 | 15 | 3 | 1 | 0.022 |
≥1 | 12 | 8 | 8.000 (1.399–45.756) |
Cmax, serum concentration after 2 h; NA, not applicable.